RxDoctor Payments Data

Harry Cheves, MD

Family Medicine · Greensboro, GANPI 1063491504

Payments from drug & device makers

$4,654in general payments, 2019–2025

Across 284 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$757
  • Boehringer Ingelheim$722
  • AstraZeneca$515
  • Lilly USA, LLC$310
  • AbbVie$204
  • Esperion Therapeutics, Inc.$193
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,654100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,654 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$113,538
Medicare patients
424
Services billed
1,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$106,020
OzempicSemaglutide77$77,606
XareltoRivaroxaban39$39,567
JardianceEmpagliflozin16$25,889
JanuviaSitagliptin Phosphate12$20,512
FarxigaDapagliflozin Propanediol11$17,300
SynthroidLevothyroxine Sodium73$6,188
Valsartan187$5,531
MyrbetriqMirabegron11$5,144
Atorvastatin Calcium458$4,011
Dexlansoprazole DrDexlansoprazole12$3,444
Olmesartan Medoxomil116$3,140
Omeprazole209$2,711
Pravastatin Sodium178$2,630
Levothyroxine Sodium253$2,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$143$106,02098 claims
Novo NordiskOzempic$757$77,60677 claims
Johnson & JohnsonXarelto$28$39,56739 claims
Boehringer IngelheimJardiance$722$25,88916 claims
AstraZenecaFarxiga$515$17,30011 claims
AbbVieSynthroid$204$6,18873 claims
Astellas Pharma US IncMyrbetriq$22$5,14411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Greensboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →